Complete Guide to DAC Pharmacokinetics
Overview
DAC is a Monoclonal Antibody (Anti-CD25) used in the Neurology therapeutic area. It is indicated for Multiple Sclerosis. Daclizumab PK simulator. Daclizumab is a humanized IgG1 monoclonal antibody that binds CD25 (IL-2 receptor alpha subunit), blocking IL-2 signaling to activated T cells. Used in relapsing multiple sclerosis. Simulate concentration-time profiles for IV and SC dosing regimens.
Mechanism of Action
DAC exerts its pharmacological effect by targeting CD25 (IL-2 receptor alpha). As a Monoclonal Antibody (Anti-CD25), it modulates this target to achieve therapeutic efficacy in Multiple Sclerosis. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published PopPK models for DAC:
| Parameter | Value |
|---|---|
| DAR | 4.0 |
| kng | 0.01 h-1 |
| DC50 | 1.0 nM |
| Dmax | 95% |
| kmax | 0.05 h-1 |
| Q DAC | 0.02 L/h |
| CL DAC | 0.013 L/h |
| V1 DAC | 3.0 L |
| V2 DAC | 2.5 L |
| CL PROTAC | 0.5 L/h |
| V1 PROTAC | 10.0 L |
| V2 PROTAC | 30.0 L |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
DAC is administered via the IV/SC route. Intravenous administration provides 100% bioavailability and allows precise control of drug exposure. Infusion duration and rate can significantly impact peak concentrations.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Neurology therapeutic area, for the treatment of Multiple Sclerosis, understanding the pharmacokinetics of DAC is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect DAC pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
- •Anti-drug antibody (ADA) formation and immunogenicity
Interactive DAC PK Simulator
Explore DAC pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of DAC?
The elimination half-life of DAC depends on patient-specific factors. Use our interactive DAC PK simulator to explore concentration-time profiles and estimate half-life under different dosing scenarios.
How is DAC administered?
DAC is administered via the IV/SC route. It is indicated for Multiple Sclerosis. As a Monoclonal Antibody (Anti-CD25), dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of DAC?
Key pharmacokinetic parameters for DAC include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate DAC dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive DAC PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.